KPIs & Operating Metrics(New)
Breakdown Of AssetsCost Of Product SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitOpex As A % Of Total Revenue %OPEX SegregationProperty And EquipmentRevenue By Category Contract Revenue From CollaborationsRevenue By Category Contract Revenue From Collaborations AnnualRevenue By Collaborative Partners AnnualRevenue By Major CustomersRevenue By Major Customers %Revenue By Major Customers AnnualRevenue By Major Customers Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Total Bottles ShippedTotal Bottles Shipped Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Gross Profit (2018 - 2025)

Historic Gross Profit for Rigel Pharmaceuticals (RIGL) over the last 8 years, with Q3 2025 value amounting to $64.7 million.

  • Rigel Pharmaceuticals' Gross Profit rose 3686.05% to $64.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $262.6 million, marking a year-over-year increase of 8648.62%. This contributed to the annual value of $160.6 million for FY2024, which is 4633.15% up from last year.
  • Rigel Pharmaceuticals' Gross Profit amounted to $64.7 million in Q3 2025, which was up 3686.05% from $97.2 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Gross Profit's 5-year high stood at $97.2 million during Q2 2025, with a 5-year trough of $16.6 million in Q1 2022.
  • Its 5-year average for Gross Profit is $39.4 million, with a median of $28.8 million in 2022.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 7941.31% in 2022, then soared by 18554.09% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Gross Profit (Quarter) stood at $19.9 million in 2021, then soared by 155.68% to $50.9 million in 2022, then plummeted by 37.17% to $32.0 million in 2023, then skyrocketed by 61.89% to $51.8 million in 2024, then rose by 24.9% to $64.7 million in 2025.
  • Its last three reported values are $64.7 million in Q3 2025, $97.2 million for Q2 2025, and $48.9 million during Q1 2025.